The immunomodulatory molecule TIGIT is expressed by chronic lymphocytic leukemia cells and contributes to anergy
T-cell immunoreceptor with Ig and ITIM domains (TIGIT) is an inhibitory checkpoint receptor that negatively regulates Tcell responses. CD226 competes with TIGIT for binding to the CD155 ligand, delivering a positive signal to the T cell. Here we studied the expression of TIGIT and CD226 in a cohort of 115 patients with chronic lymphocytic leukemia (CLL) and report expression of TIGIT and CD226 by leukemic cells. By devising a TIGIT/CD226 ratio, we showed that CLL cells favoring TIGIT over CD226 are typical of a more indolent disease, while those favoring CD226 are characterized by a shorter time to first treatment and shorter progression-free survival after first treatment. TIGIT expression was inversely correlated to the B-cell receptor (BCR) signaling capacity, as determined by studying BTK phosphorylation, cell proliferation and interleukin- 10 production. In CLL cells treated with ibrutinib, in which surface IgM and BCR signaling capacity are temporarily increased, TIGIT expression was downmodulated, in line with data indicating transient recovery from anergy. Lastly, cells from patients with Richter syndrome were characterized by high levels of CD226, with low to undetectable TIGIT, in keeping with their high proliferative drive. Together, these data suggest that TIGIT contributes to CLL anergy by downregulating BCR signaling, identifying novel and actionable molecular circuits regulating anergy and modulating CLL cell functions.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:108 |
|---|---|
| Enthalten in: |
Haematologica - 108(2023), 8 vom: 01. Aug., Seite 2101-2115 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Arruga, Francesca [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Antigens, Differentiation, T-Lymphocyte |
|---|
| Anmerkungen: |
Date Completed 02.08.2023 Date Revised 02.08.2023 published: Electronic Citation Status MEDLINE |
|---|
| doi: |
10.3324/haematol.2022.282177 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM351662197 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM351662197 | ||
| 003 | DE-627 | ||
| 005 | 20231226051927.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.3324/haematol.2022.282177 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1172.xml |
| 035 | |a (DE-627)NLM351662197 | ||
| 035 | |a (NLM)36655432 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Arruga, Francesca |e verfasserin |4 aut | |
| 245 | 1 | 4 | |a The immunomodulatory molecule TIGIT is expressed by chronic lymphocytic leukemia cells and contributes to anergy |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 02.08.2023 | ||
| 500 | |a Date Revised 02.08.2023 | ||
| 500 | |a published: Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a T-cell immunoreceptor with Ig and ITIM domains (TIGIT) is an inhibitory checkpoint receptor that negatively regulates Tcell responses. CD226 competes with TIGIT for binding to the CD155 ligand, delivering a positive signal to the T cell. Here we studied the expression of TIGIT and CD226 in a cohort of 115 patients with chronic lymphocytic leukemia (CLL) and report expression of TIGIT and CD226 by leukemic cells. By devising a TIGIT/CD226 ratio, we showed that CLL cells favoring TIGIT over CD226 are typical of a more indolent disease, while those favoring CD226 are characterized by a shorter time to first treatment and shorter progression-free survival after first treatment. TIGIT expression was inversely correlated to the B-cell receptor (BCR) signaling capacity, as determined by studying BTK phosphorylation, cell proliferation and interleukin- 10 production. In CLL cells treated with ibrutinib, in which surface IgM and BCR signaling capacity are temporarily increased, TIGIT expression was downmodulated, in line with data indicating transient recovery from anergy. Lastly, cells from patients with Richter syndrome were characterized by high levels of CD226, with low to undetectable TIGIT, in keeping with their high proliferative drive. Together, these data suggest that TIGIT contributes to CLL anergy by downregulating BCR signaling, identifying novel and actionable molecular circuits regulating anergy and modulating CLL cell functions | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 7 | |a Antigens, Differentiation, T-Lymphocyte |2 NLM | |
| 650 | 7 | |a Cytokines |2 NLM | |
| 650 | 7 | |a Receptors, Immunologic |2 NLM | |
| 650 | 7 | |a TIGIT protein, human |2 NLM | |
| 700 | 1 | |a Rubin, Marta |e verfasserin |4 aut | |
| 700 | 1 | |a Papazoglou, Despoina |e verfasserin |4 aut | |
| 700 | 1 | |a Iannello, Andrea |e verfasserin |4 aut | |
| 700 | 1 | |a Ioannou, Nikolaos |e verfasserin |4 aut | |
| 700 | 1 | |a Moia, Riccardo |e verfasserin |4 aut | |
| 700 | 1 | |a Rossi, Davide |e verfasserin |4 aut | |
| 700 | 1 | |a Gaidano, Gianluca |e verfasserin |4 aut | |
| 700 | 1 | |a Coscia, Marta |e verfasserin |4 aut | |
| 700 | 1 | |a Laurenti, Luca |e verfasserin |4 aut | |
| 700 | 1 | |a D'Arena, Giovanni |e verfasserin |4 aut | |
| 700 | 1 | |a Allan, John N |e verfasserin |4 aut | |
| 700 | 1 | |a Furman, Richard R |e verfasserin |4 aut | |
| 700 | 1 | |a Vaisitti, Tiziana |e verfasserin |4 aut | |
| 700 | 1 | |a Ramsay, Alan G |e verfasserin |4 aut | |
| 700 | 1 | |a Deaglio, Silvia |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Haematologica |d 1947 |g 108(2023), 8 vom: 01. Aug., Seite 2101-2115 |w (DE-627)NLM000081892 |x 1592-8721 |7 nnns |
| 773 | 1 | 8 | |g volume:108 |g year:2023 |g number:8 |g day:01 |g month:08 |g pages:2101-2115 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.3324/haematol.2022.282177 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 108 |j 2023 |e 8 |b 01 |c 08 |h 2101-2115 | ||